AbbVie’s Q1 Revenue Growth Outpaces Big Pharma Peers

Bouncing back from the pandemic more strongly than its peers, AbbVie sees 40% growth for Botox and Juvederm, a good launch for Ubrelvy and continued strength from its mainstays.

Business report
AbbVie delivered Q1 sales growth while peers struggled with pandemic impacts

AbbVie Inc. outperformed its big pharma peers during the first quarter, reporting 5.2% revenue growth year-over-year, totaling just over $13bn, with notable growth in its immunology, aesthetics and neuroscience portfolios. Much of that resilience came from business brought in by its 2020 acquisition of Allergan plc, and CEO Rick Gonzalez played up the company’s diversity in presenting the Q1 results.

“We are clearly demonstrating that we have created a stronger and much more diverse company with the scale and flexibility...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.